StemCell Therapy

Updated and long-term follow-up analyses from two clinical trials evaluating brentuximab vedotin (Adcetris; Seattle Genetics/Takeda) and nivolumab (Opdivo; BristolMyers Squibb) in frontline Hodgkin lymphoma patients aged 60 years and older and in relapsed or refractory classical Hodgkin lymphoma were presented at the 61st annual meeting of the American Society of Hematology (ASH) taking place December 7-10, 2019 in Orlando, Florida.

According to the American Cancer Society, approximately 8,110 cases of Hodgkin lymphoma will be diagnosed in the United States during 2019 and 1,000 will die from the disease. Approximately half of all newly diagnosed Hodgkin lymphoma patients have Stage III/IV disease. According to the Lymphoma Coalition, over 62,000 people worldwide are diagnosed with Hodgkin lymphoma each year and approximately 25,000 people die each year from this cancer.

Antibody-drug conjugateBrentuximab vedotin is an antibody-drug conjugate or ADC directed to CD30, a defining marker of classical Hodgkin lymphoma. The drug includes an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE). The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumor cells.

Antibody-drug Conjugates are highly targeted biopharmaceutical drugs that combine monoclonal antibodies specific to surface antigens present on particular tumor cells with highly potent anti-cancer agents linked via a chemical linker.

With five approved drugs on the market, ADCs have become a powerful class of therapeutic agents in oncology and hematology.

Continued evaluationWe continue to evaluate brentuximab vedotin in combination with novel therapies, such as checkpoint inhibitors, with the goal of identifying new options for CD30-expressing lymphomas where there is high unmet need, said Roger Dansey, MD, Chief Medical Officer at Seattle Genetics.

The data presentations at the annual meeting reinforces our strong commitment to the brentuximab vedotin clinical development program, potentially moving into new patient populations and novel combination treatment strategies, Dansey added.

Frontline therapyData were presented from an updated analysis from the phase II clinical trial evaluating brentuximab vedotin in combination with nivolumab as frontline therapy for Hodgkin lymphoma patients aged 60 years and older. Data were reported from 21 patients, and the median age was 72 years. The majority of patients (76%) had stage III/IV disease at the time of diagnosis.

These results were highlighted in an oral presentation by Christopher A. Yasenchak, MD, Willamette Valley Cancer Institute and Research Center/US Oncology Research, Oregon. [1]

The trial included 19 response-evaluable patients, 18 patients (95%) had an objective response, including 13 patients (68%) with a complete response and five patients (26%) with a partial response.

All response-evaluable patients experienced tumor reduction (complete response + partial response + stable disease) following treatment with brentuximab vedotin in combination with nivolumab. Median duration of response was not yet reached and the maximum duration of response was 22 months and ongoing (95% CI: 7.06, -).

The most common treatment-related adverse events of any grade occurring in at least 20% of patients were fatigue, diarrhea, pyrexia, infusion related reaction, peripheral motor neuropathy, peripheral sensory neuropathy and increase in lipase.

One treatment-related serious adverse event was pyrexia. Fifty-seven percent of patients (12/21) had at least one treatment-related adverse event greater than or equal to Grade 3, most commonly increase in lipase (24%, 5/21), peripheral motor neuropathy and peripheral sensory neuropathy (each 14%, 3/21), and fatigue and hyponatremia (each 10%, 2/21).

These data suggest that brentuximab vedotin + nivolumab is an active treatment with an encouraging CR rate (72%) and appears well tolerated. The results also suggest that with further follow-up and validation, treatment with brentuximab vedotin + Nivo may improve patient outcomes.

Relapsed or Refractory Hodgkin LymphomaA second presentation reported data from 93 patients with relapsed or refractory classical Hodgkin lymphoma after failure of frontline therapy who received the combination regimen of brentuximab vedotin plus nivolumab.

After completion of the fourth cycle of treatment, patients were eligible to undergo an autologous stem cell transplant (ASCT). The median age of patients was 34 years.

These results were highlighted in an oral presentation by Alison J. Moskowitz, MD, Memorial Sloan Kettering Cancer Center, New York, NY. [2]

The study results of this trial showed that of the 91 treated patients, 85% (77/91) had an objective response, including 67% (61/91) with a complete response, 16 patients with a partial response and six patients had stable disease.

From the ninety-one treated patients, sixty-seven patients received an ASCT per trial protocol with no additional salvage therapy. For all treated patients, the two-year progression-free survival (PFS) was 79% (95% CI: 68%, 87%). For the 67 patients who received an ASCT per trial protocol, the two-year PFS was 92% (95% CI: 80%, 97%). Median follow-up for all treated patients was 24.2 months (range 1.8-41.7) and the median PFS was not reached. Estimated overall survival at two years was 94% (95% CI: 85%, 97%) and median overall survival was not yet reached.

Peripheral immune signatures were consistent with an activated T-cell response. Prior to ASCT, the most common adverse events of any grade occurring in more than 20% of patients were nausea, infusion related reaction, fatigue, diarrhea, pruritus, headache, vomiting and pyrexia. Other adverse events included peripheral neuropathy in 16 patients (18%) and neutropenia in six patients (7%). Two patients (2%) discontinued treatment due to adverse events, Grade 3 peripheral neuropathy and increased gamma-glutamyltransferase. Serious adverse events occurred in 14 patients (15%), including pneumonia, pneumonitis and pyrexia (two patients each); and Grade 3 Guillain-Barre syndrome (one patient).

Reference[1] Yasenchak CA, Bordoni R, Yazbeck V, Patel-Donnelly D, Anderson T, Larson T, Newhook T, Mei M, et al. Phase II Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged 60 Years. 61st annual meeting of the American Society of Hematology (ASH). Program: Oral and Poster Abstracts. Type: Oral. Abstract 237. Session: 624. Hodgkin Lymphoma and T/NK Cell LymphomaClinical Studies: Immunotherapy Approaches in Hodgkin Lymphoma Hematology Disease Topics & Pathways: Diseases, Biological, antibodies, Therapies, Non-Hodgkin Lymphoma, T-Cell Lymphoma, Lymphoid Malignancies.[Abstract][2] Moskowitz AJ, Advani R, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, LaCasce AS, Christian BA, et al. Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase I/II Study. 61st annual meeting of the American Society of Hematology (ASH).Program: Oral and Poster AbstractsType: Oral Abstract 238. Session: 624. Hodgkin Lymphoma and T/NK Cell LymphomaClinical Studies: Immunotherapy Approaches in Hodgkin Lymphoma. Hematology Disease Topics & Pathways:Diseases, Biological, Therapies, Hodgkin Lymphoma, checkpoint inhibitors, immunotherapy, Lymphoid Malignancies. [Abstract]

Read more here:

ASH 2019: Brentuximab Vedotin in Combination with Nivolumab in Frontline and R/R Hodgkin Lymphoma - OncoZine

Cancer is a disease caused by unhealthy cells inside the body growing out of control. Lung cancer is the uncontrolled growth of abnormal cells that start off in one or both lungs.

In the United States, is the form of . It is also the most common cause of cancer death in the U.S.

Contents of this article:

Lung cancer can cause a number of complications in the lungs and in other parts of the body. Here are some of the most common complications:

Some of the more common lung cancer symptoms are caused by complications in the lungs.

According to , these complications can lead to the following symptoms:

Pneumonia is a possible symptom of complications in the lungs caused by cancer.

is numbness and tingling feelings in the hands and feet due to damaged nerve tissue. It can be a .

Neuropathy is caused by tumors that grow near the nerves in the arm or shoulder. A compresses the nerves leading to pain and weakness.

This is the in the membrane that covers the lungs. The fluid can then press against the lungs causing breathlessness.

Lung cancers can sometimes affect the heart when they develop near it or close to major blood vessels. This can cause fluid to press against the heart, which may lead to a number of issues.

These issues include:

Depending on its location, a tumor may block a persons airways or food pipe.

A tumor may grow into an airway in the lung and block it. This may lead to other issues, such as pneumonia or shortness of breath.

Lung cancers that grow near a persons food pipe can cause complications, making it difficult for the person to swallow.

Cancers near a foodpipe may lead to a person feeling pain when food passes through to their stomach.

Another serious complication of lung cancer is that it may spread to other parts of the body. Some lung cancer cells can travel through the lymphatic system or through the bloodstream.

If this happens, the cells can become lodged somewhere else in the body. Cancerous cells can then grow in these new locations, causing further cancers.

According to , lung cancer is most likely to spread to:

There are a number of ways to treat all of these different complications. The choice of treatment will vary depending on a number of factors, which include the type of complication, the age, and the general health of the patient.

Here are different treatments for the variety of complications listed above:

Numbness and tingling in the hands or feet may be treated with medication.

Neuropathy as a complication of lung cancer can lead to discomfort. There are many ways to treat the symptoms of neuropathy, including:

Pleural effusion can be treated by slowly draining away the fluid. In order to do this, a tube is inserted into the chest through a small cut.

A person may spend a few days in hospital after this treatment. If the fluid builds up again, they may need to have it drained a further time.

A person with pleural effusion may also have one of the following procedures:

Heart complications can occur if fluid presses against blood vessels because of a tumor. This can be treated in the following ways:

There are a number of procedures to treat lung cancer if it blocks a persons airways. These include the following:

Complications caused by lung cancer can occur over time. They tend to appear as the disease develops.

If a persons lung cancer is detected early, then they have a much higher chance of surviving the disease. Its important for a person to understand the symptoms so that they can get an early diagnosis.

Unfortunately, most cases of lung cancer are diagnosed in the later stages. This is because many of the symptoms or complications of the disease tend not to occur until the cancer is advanced.

Therefore, the individual outlook depends on a number of factors including the type of cancer, how far it has developed, and the persons age and general health.

Written by Adam Rowden

Follow this link:

Medical News Today: Lung cancer complications: Signs, treatment, and outlook - Stock Daily Dish

Pain under the left armpit can be concerning, and many people associate any pain on the left side of their body with a heart attack. However, most of the time, pain under the left armpit has a less serious cause.

The armpit is a complex meeting point for muscles and connective tissues, lymph nodes, and blood vessels. As such, many issues in this area can lead to pain.

Causes range from pulled muscles and mild allergic reactions to more severe issues, such as an underlying infection.

While many of the causes of left armpit pain are not harmful in the long term, anyone experiencing breathing difficulties and pain in their chest, jaw, or neck should see a doctor immediately.

Causes of left armpit pain include:

Many muscles around the shoulder and armpit can cause pain if a person injures them.

People can pull a muscle when reaching for an object, twisting incorrectly, or overstretching.

People who exercise regularly, especially those who do weight training, may be more likely to experience muscle pulls and strains.

In these cases, the pain should go away over time, as long as the individual rests the injured muscle and does gentle stretches.

If the pain does not go away after about a week, it is best to see a doctor.

Armpits are a frequent location for allergic reactions, which could cause pain under the left armpit or both armpits.

Most allergic reactions in this area will occur due to chemicals people apply to their bodies or clothes that touch the armpits.

Possible allergens include:

These products may contain chemicals or perfumes that irritate the skin. A rash may also form.

Anyone who suspects that their skin is sensitive to a particular allergen should note the products they used that day and report them to a dermatologist.

Allergy testing may help find the irritating product. Avoiding products with any harsh chemicals or other ingredients can also improve symptoms in these cases.

Simple cosmetic procedures, such as shaving or waxing, can also be to blame for pain under the armpit. These hair removal techniques may lead to other issues, such as ingrown hairs, cysts, or general irritation and chafing in the armpit.

A skin infection under the armpit may cause itching and pain. Bacteria thrive in warm, damp environments such as the armpits.

An overgrowth of bacteria in this area may lead to an infection, which could cause redness, swelling, and pain, among other symptoms.

Other forms of infection, such as fungal infections due to ringworm or yeast, may also cause similar pain and irritation in the area.

Mild skin infections should clear up without treatment if a person keeps the area clean and dry. However, a doctor may recommend antibiotic creams or medications to treat more severe cases.

Hidradenitis is a chronic condition that causes similar symptoms to severe acne. Hidradenitis occurs due to clogged hair follicles and glands. It is common in areas such as the armpits, where the skin rubs together.

Hidradenitis can lead to multiple cysts or boils developing in the area. In addition to these breakouts, the person will likely experience pain and tenderness.

Doctors can treat hidradenitis with anti-inflammatory medications. Some cases may require surgery.

The varicella zoster virus causes chickenpox and shingles. Breakouts of both illnesses are possible under the armpits, although chickenpox usually begins on the face, back, and chest.

A shingles rash usually develops as a single strip on one side of the face or body, left or right. A person with shingles may also experience:

A person may feel pain and tingling in the area before the visible rash develops.

A doctor may prescribe antiviral medications to speed up the healing process, as well as pain medications to help ease symptoms.

Lymph nodes are small, bean shaped bundles of tissue that play a vital role in the immune system. Lymph nodes help filter toxins from the lymph and deliver white blood cells to help fight disease.

The armpit houses a large number of lymph nodes. Lymph nodes swell as part of an overall reaction by the immune system, such as to an infection or illness.

Swollen lymph nodes in the armpit may cause:

If the swelling does not go down after an infection, such as the common cold, goes away, or the person is not feeling any other symptoms, they should speak to a doctor.

Psoriasis is an autoimmune condition that leads to an overgrowth of skin cells. The buildup of skin cells forms patches called plaques. These plaques can cause symptoms such as itching and pain.

Psoriasis plaques can form anywhere, including the armpit. Some forms of psoriasis are more common in this area, including inverse psoriasis.

Psoriasis treatment typically includes both topical and oral medications to control symptoms.

Nerve damage may also cause pain under the armpit. Nerve damage can be the result of a physical injury, such as one from overuse during sports or from an accident or fall.

Nerve damage can feel like:

Certain conditions, such as diabetes, may also lead to nerve damage or neuropathy. The National Institute of Diabetes and Digestive and Kidney Diseases note that up to half of people with diabetes have peripheral neuropathy, which is nerve damage.

While peripheral neuropathy typically affects the feet and legs, it may also affect the arms in some individuals. Diabetes treatment may help slow nerve damage progression.

Angina occurs due to a lack of oxygen-rich blood flow to the heart. This can be because one of the arteries leading to the heart is narrow or blocked.

Angina causes chest pain and discomfort, which is sometimes severe. It may also cause pressure and pain in other areas, including the:

Some people may also experience a feeling similar to indigestion.

Angina is a symptom of an underlying heart condition, for example, coronary heart disease, which can lead to a heart attack.

There are also many other types of angina. Anyone who suspects they have angina should talk to their doctor.

In rare cases, pain under the left armpit that does not go away may be a sign of a cancerous growth, including breast cancer.

Cancer can cause the lymph nodes under the armpit to swell painfully. An individual may notice a lump under their arm or in their armpit that causes persistent pain or discomfort.

Underarm pain may also be the result of a specific cancer treatment, such as lymph node removal or mastectomy.

Anyone noticing texture changes or lumps in their chest or breast tissue should seek medical attention.

Treatment options for cancer will depend on its stage, which refers to how much it has spread. In general, earlier stages are easier to treat.

Anyone noticing the following symptoms along with left armpit pain should seek immediate medical attention:

A doctor can also diagnose and treat pain from other issues, such as infections or swollen lymph nodes.

Pain under the left armpit from sources such as a pulled muscle should go away within about a week in most cases. Anyone who experiences symptoms beyond this time frame should see a doctor for a full diagnosis.

There are many possible causes of pain under the left armpit. The person may have pulled a muscle or may have swollen lymph nodes from an infection.

Other causes can be more serious, such as angina. Anyone concerned about their symptoms should see a doctor for a full diagnosis and treatment.

Originally posted here:

Pain under left armpit: Causes and what to do - Medical News Today

Results of a recent study suggest a possible role for tumor necrosis factor- (TNF-) in the development of peripheral neuropathy (PN) in patients with multiple myeloma (MM) treated with bortezomib. The studys results were published in the Annals of Hematology.

Inthis study, patients with MM (N=35) were given a maximum of 8 cycles ofbortezomib in addition to dexamethasone. Patients underwent tests of nervefunction, and their serum levels of TNF- were also measured. This study alsoincluded an analysis of the effects of an anti-TNF- monoclonal antibodytherapy in Wistar rats (N=36) that received bortezomib.

Evaluablepatients were stratified based on the cumulative dosages of bortezomib theyreceived. A total of 16 patients (48.5%) had cumulative dosages of less than 39mg/m2, and 17 (51.5%) each received 39 mg/m2 or more of bortezomib.

Amongpatients who received lower cumulative dosages of bortezomib, 43.8% (n=7)experienced PN, compared with an incidence of PN of 82.4% (n=14) among patientswho received 39 mg/m2 or more of bortezomib (P <.05).Grade 3 PN was reported for 2 patients in the higher-dose group.

Baselineserum TNF- levels did not significantly differ between patients whoexperienced PN and those who did not. With bortezomib treatment, TNF- levelsrose overall, but increases were most significant among patients who developedPN of grades 2 to 3. The investigators also reported that most patients withTNF- levels higher than 65 pg/mL had neuropathy symptoms.

Inthe rat model, poorer nerve conduction velocity and evidence of mechanicalallodynia appeared to be associated with bortezomib therapy. Among rats treatedwith bortezomib, however, treatment with the anti-TNF- monoclonal antibody wasassociated with less neurological dysfunction.

Developmentof new neuroprotective agents against TNF- may be a promising therapeuticstrategy to prevent the development of neuropathy, wrote the studyinvestigators in their report.

Reference

Zhao W, Wang W, Li X, et al. Peripheral neuropathy following bortezomib therapy in multiple myeloma patients: association with cumulative dose, heparanase, and TNF-. Ann Hematol. doi: 10.1007/s00277-019-03816-6

Read more from the original source:

Potential Link Between Tumor Necrosis Factor- and Peripheral Neuropathy Observed With Bortezomib Treatment in Multiple Myeloma - Oncology Nurse...

Thediabetic neuropathy markethas witnessed growth from relentless efforts of various healthcare proponents in expanding the array of various therapies and first line drugs in treating the underlying pain. Players have been able to meet the patient needs because of expanding understanding of physiopathology that promote neuropathic pain in diabetes. Most first line drug therapies notably focus on mitigating toxic effects of hyperglycemia. Several players in the diabetic neuropathy market have been benefitting from the introduction of guidelines that help develop therapies that can optimize pain.

The competitive landscape of the diabetic neuropathy market is characterized by fair degree of fragmentation. A handful of players hold sizable shares in the market. Top names in the diabetic neuropathy market are Janssen Pharmaceuticals, Eli Lilly and Company, Cephalon, NeuroMertrix, and Johnson and Johnson. One of the key strategies they increasingly adopt to consolidate their shares is mergers and acquisitions.

During 2017 2025, the global diabetic neuropathy market is expected to clock a CAGR of 5.4%. By the end of this period, the worth of the global market is anticipated to be US$5.718 bn.

Request a PDF Sample of Diabetic Neuropathy MarketReport

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2199

Prevalence and Complexity Of Diabetic Peripheral Neuropathy Represents Unmet Need

Of the various disorder types, diabetic peripheral neuropathy has attracted the attention of pharmaceutical and biotech companies. By 2025-end, the segment is expected to account for a major share in the global diabetic neuropathy market. The complexity of the type has attracted vast attention of the healthcare industries around the world. The marked prevalence of diabetic peripheral neuropathy adds to its disabling nature. The higher mortality and morbidity of distal symmetrical polyneuropathy is also propelling investments in this area in the global diabetic neuropathy market.

In developed nations, the prevalence of diabetes is increasing at rapid pace. According to recently disclosed statistics by International Diabetes Federation, by 2045 629 million people will be living with diabetes, and currently account for more than 12% of the total spending by adult populations. One of the most complication is diabetic neuropathy. Hence, the condition has attracted groundswell of interest in these nations, such as in the U.S. and the U.K. Further, in recent years, a fast emerging category that is attracting attention of companies in the diabetic neuropathy market is treatment-induced neuropathy in diabetes. Constant advances in understanding of the underlying pathogenesis of diabetic peripheral neuropathy over the last decade have expanded the prospects of the diabetic neuropathy market.

Request for a Discount on Diabetic Neuropathy Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=2199

Asia Pacific Fast Emerging as Key Diabetic Neuropathy Market

In the light of developed markets, North America and Europe have emerged as prominent regional markets. A shared factor underpinning the evolution of both these markets are expanding interest in pathophysiological mechanisms. On the other hand, Asia Pacific is emerging as a vastly lucrative region in the global diabetic neuropathy market. This is attributed to the substantial clinical developments in understanding diabetic complications.

Expanding Pharmacological Classes of Drugs Provides New Revenue Base

Lifesciences companies in the global diabetic neuropathy market find it worthwhile and necessary to develop therapies that can target multiple metabolic pathways. Key of these are hyperglycemia, toxic adiposity, mitochondrial dysfunction, and polyol pathway. Promising candidates to emerge in recent years are accumulation of advanced glycation end products (AGEs). Growing research on improving the clinical efficacy of antidepressants and anticonvulsants will likely expand the outlook of the global diabetic neuropathy market.

Of note, developed as developed markets are seeing expanding research in pharmacological classes of drugs. The development of these drugs is fueled by the adoption of multimodal and multidisciplinary approaches. Further, growing focus on developing second or third line treatment is also unlocking new potential in the diabetic neuropathy market.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving method-ologies and leveraging existing data repositories.TMR believes that unison of solutions for clients-specific problems with right methodology of re-search is the key to help enterprises reach right decision.

ContactMr. Rohit BhiseyTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY 12207United StatesTel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Email:[emailprotected]Website:http://www.transparencymarketresearch.comBlog:https://theglobalhealthnews.com/

Read this article:

Diabetic Neuropathy Market: Technological Growth Map over Time to Understand the Industry Growth Rate - Montana Ledger

Damage to the nerves that control the regulation of involuntary function due to high levels of blood glucose may cause a condition called autonomic neuropathy. An example of body functions such as heart rate, digestion, blood pressure, sexual activity, and perspiration. Cardiac autonomic neuropathy occurs when the heart is affected by nerve damage. Diabetes mellitus patient commonly suffers from cardiac autonomic neuropathy. More than 26 million people in the Unites States get affected by diabetes mellitus. With the increase in age and duration of diabetes mellitus, a prevalence rate of cardiac autonomic neuropathy increase. Cardiac Autonomic Neuropathy is the reason for several cardiac dysfunctions and many medical symptoms which include exercise intolerance, silent ischemia, postural hypotension, resting tachycardia, perioperative instability, and cardiomyopathy.

To Remain Ahead Of Your Competitors, Request for a Sample Here @https://www.persistencemarketresearch.com/samples/14518

Cardiac Autonomic Neuropathy treatment market involves aggressively treating cardiovascular risk factors like hypertension. Cardiac autonomicdeficiency of essential fatty acids, increased oxidative stress, autoimmune damage, and formation of advanced glycosylation end products. Other therapies include in Cardiac autonomic neuropathy treatment include Aldose reductase inhibitor and angiotensin receptor blocker.

Cardiac Autonomic Neuropathy Treatment Market: Drivers and Restraints

In diabetic patients, Cardiac Autonomic Neuropathy characterizes one of the main causes of morbidity and mortality as well as is responsible for cardiac arrhythmias and sudden death which is increasing the demand for cardiac autonomic neuropathy treatment market. Increase in aging population as the well societal influence and changing lifestyles are also the cause of increasing Cardiac autonomic neuropathy treatment market in the world. According to WHO report, more than 23 million people in the United States and an estimated 250 million worldwide are affected by diabetes mellitus. In diabetic patient Cardiac autonomic neuropathy is very common and leads to abnormalities in heart flow rate as well as vascular and peripheral dynamics and reduced quality of life are the drivers for Cardiac autonomic neuropathy treatment market. Some of the Cardiac autonomic neuropathy therapies has shown promising initial result but yet to be validated as well Cardiac autonomic neuropathy treatment management depends on aggressive strategies due to the absence of direct treatment could be the possible restraint for the Cardiac autonomic neuropathy treatment market. Poor reimbursement policies by government and private players also challenge the Cardiac autonomic neuropathy treatment market.

Cardiac Autonomic Neuropathy Treatment Market: Segmentation

Cardiac autonomic neuropathy treatment market is segmented into treatment type which includes pharmacological agents as well as inhibitors and by distribution channel.

Cardiac Autonomic Neuropathy Treatment Market: Overview

Due to increasing aging population and diabetes mellitus, the global market for Cardiac autonomic neuropathy treatment market is expected to gain pull during the forecast period. It is expected centrally acting Cardiac autonomic neuropathy treatment market segment to hold the dominant share in the global Cardiac autonomic neuropathy treatment market due to increasing number of diabetic patients. Also, the increase in number launches of the new drugs cardiac autonomic neuropathy treatment market is increasing globally. Increasing competition among ading drug firms in the market to develop newer drugs tends to drive the cardiac autonomic neuropathy treatment market towards the growth rate.

Cardiac Autonomic Neuropathy Treatment Market: Region-wise Outlook

Based on geographic region, the Cardiac autonomic neuropathy treatment market is segmented into seven significant regions:

North America, Latin America, Europe, Asia-pacific, and Middle East & Africa.

North America is the largest in Cardiac autonomic neuropathy treatment market, owing to high number of diabetes mellitus patient and awareness among patients regarding the harmful effects orpulation as well as growing healthcare expenditure is the reason for significant revenue generation from this region in Cardiac autonomic neuropathy treatment market. Europe is the second largest in Cardiac autonomic neuropathy market due to advancement in technologies and change in lifestyles.

Asia-Pacific is expected to grow at faster rate in the upcoming period due to the increase in the prevalence of diabetes mellitus thus boosting the Cardiac autonomic neuropathy treatment market growth.

Make An Inquiry To Customize This Report @https://www.persistencemarketresearch.com/request-customization/14518

Cardiac Autonomic Neuropathy Treatment Market: Key Market Participants

Some of the key players in Cardiac autonomic neuropathy treatment market are

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.

Read more:

Cardiac Autonomic Neuropathy Treatment Market by Size | Growth | Analysis | Trends and Forecasts to 2017 2025 - chronicles24

Researchers at Griffith University will undertake a comprehensive assessment of nerve function of people with diabetes to learn more about the onset of peripheral neuropathy.

Neuropathy is the highest reported complication of diabetes worldwide. The most common form of neuropathy is distal symmetrical neuropathy. It causes significant suffering, including loss of sensation in the feet and eventually in the hands.

Around 1.7 million Australians have diabetes, according to Diabetes Australia, and around half of those people could be expected to develop some type of neuropathy. The number of people with diabetes has experienced a fourfold increase, from 108 million adults worldwide in 1980 to 422 million in 2014.

Although diabetic neuropathies are common, surprisingly little is known about the condition and its onset, which is why Eva Sierra Silvestre is leading the DIANE (Diabetic neuropathies) research project, which will assess the function, structure and mechanics of the nervous system in people with diabetes.

What we are planning to do is to create a very comprehensive assessment of nerve function in people with diabetes, she said. By doing that, we may be able to predict or be able to improve prevention and management later on.

An issue with this condition and current screening practices is that sometimes the onset can go unnoticed, so the study will aim to find ways to pick up on peripheral neuropathy in its early stages.

Early detection of diabetic complications is crucial for an effective management of the condition, Ms Sierra Silvestre, a PhD candidate at the Menzies Health Institute Queensland, said.

In research, nerve function in the feet has been studied more than in hands. Typically, it is thought that hands are affected in a later stage but the research team thinks that these changes may occur earlier than what we think. As such, the DIANE research project will focus on assessing subjects hands for any sign of nerve damage.

The researchers are looking for people with diabetes, with and without symptoms of peripheral neuropathy, such as numbness or pain.

Participants will be required to attend three sessions, one each at Griffith Universitys Nathan campus, QUT at Kelvin Grove, and QScan at Red Hill.

To learn more about the study, visit the DIANE Diabetic Neuropathies research project website.

Ms Sierra Silvestres study is one of two ongoing into peripheral neuropathies at Griffith University. Dr Brooke Coombes is also looking for study participants as she investigates a new approach to managing exercise for people with the condition.

Read more:

Study to search for early signs of peripheral neuropathy in people with diabetes - Griffith News

Akcea Therapeutics and Ionis Pharmaceuticals announced the launch of a Phase 3 clinical trial evaluating the safety and efficacy of AKCEA-TTR-LRx (ION-682884) for the treatment of adults with familial amyloid polyneuropathy (FAP).

The global, open-label, randomized NEURO-TTRansform trial (NCT04136184) is expected to start in December. It is recruiting approximately 140 participants ages 18 to 82, diagnosed with stage 1 or 2 FAP, at the Ionis Investigative Site in Boston.

AKCEA-TTR-LRx is a second-generation RNA-targeted therapy in development for the treatment of all forms of transthyretin amyloidosis, including the hereditary (hATTR) and wild-type form of the disease (ATTRwt).

It works by preventing the RNA sequence of the TTR gene, which is defective in people with hATTR, from being translated into a protein. This reduces the buildup of abnormal amyloid deposits that accumulate in several tissues, slowly causing damage and eventually giving rise to symptoms associated with FAP or the other form of hATTR, called familial amyloid cardiomyopathy (FAC). Of note, RNA is the molecule that serves as the template for the production of a protein.

AKCEA-TTR-LRx was originally discovered by Ionis through its proprietary LIgand Conjugated Antisense (LICA) technology platform. It is now being co-developed by Ionis and its affiliate, Akcea.

NEURO-TTRansform will compare the effects of AKCEA-TTR-LRxto the placebo arm of a previous Phase 2/3 trial (NCT01737398), also sponsored by Ionis, that investigated the safety and efficacy of Tegsedi(inotersen) in people with FAP, compared with a placebo.

Once enrolled in NEURO-TTRansform, participants will be randomly assigned to receive subcutaneous (under-the-skin) injections of AKCEA-TTR-LRx every four weeks, or Tegsedi once a week. All study participants also will receive daily supplemental doses of the recommended daily allowance of vitamin A.

Those who are initially assigned to Tegsedi (20 out of the 140 expected to enroll), will cross over to AKCEA-TTR-LRx after 35 weeks.

The studys main goals, which will be assessed at 66 weeks, include analyzing changes from the studys start in the levels of TTR found in the serum, as well as changes in the scores of the modified Neuropathy Impairment Score +7 (mNIS+7) and of the Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QoL-DN).

The mNIS+7 is a measure of neurological impairment that evaluates muscle weakness, sensation, reflexes, nerve conduction, and autonomic function; the Norfolk QoL-DN evaluates the impact of neuropathy on individuals quality of life.

An interim analysis is planned at 35 weeks to assess changes from the studys start in the levels of TTR found in the serum and in mNIS+7 scores.

Patients enrolled in NEURO-TTRansform will be followed for 85 weeks. After completing the study, they will have the option to enroll in an open-label extension study.

The initiation of the TTRransform Phase 3 program represents an expansion of our dedication and commitment to the ATTR community. The NEURO-TTRansform study is the first of two Phase 3 studies that we expect to initiate with AKCEA-TTR-LRx. Our Phase 1 data are encouraging and we are excited about the possibility of delivering a significant advancement for people living with hATTR amyloidosis, Damien McDevitt, PhD, Akceas interim CEO, said in a press release.

In a previous Phase 1 trial (NCT03728634) sponsored by Ionis, it was shown that monthly 90-mg injections of AKCEA-TTR-LRx could lower the levels of transthyretin (TTR), the protein involved in FAP, by up to 94% after 13 weeks of treatment in a group of healthy volunteers.

The Phase 1 data of AKCEA-TTR-LRx are consistent with the clinical profile seen across our other LICA programs, highlighting the potential of LICA-engineered therapies to address both rare and more common diseases, said Brett P. Monia, PhD, chief operating officer of Ionis.

We remain dedicated to advancing this important clinical development program as rapidly as possible and are hopeful about the prospect of bringing a new safe and effective treatment to people living with the devastating symptoms of hATTR amyloidosis in the years ahead, Monia added.

The company also launched the Phase 3 CARDIO-TTRansform clinical trial (NCT04136171), to test AKCEA-TTR-LRx in people with transthyretinmediated amyloid cardiomyopathy (ATTR CM), or FAC. The trial is not yet enrolling.

Joana is currently completing her PhD in Biomedicine and Clinical Research at Universidade de Lisboa. She also holds a BSc in Biology and an MSc in Evolutionary and Developmental Biology from Universidade de Lisboa. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells cells that make up the lining of blood vessels found in the umbilical cord of newborns.

Total Posts: 2

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Tcnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.

Read this article:

Phase 3 Trial of Investigative FAP Therapy AKCEA-TTR-LRx Launching - FAP News Today

AMA recently published a detailed study of over 180+ pages in its repository on Neuropathy Pain Treatment market covering interesting aspects of market with supporting development scenario till 2025. The study provides market size break-up by revenue and volume* for emerging countries and important business segments along with commentary on trending factors, growth drivers. Profiled players in study from the coverage used under bottom-up approach are Pfizer [United States], Depomed [United States], Eli Lilly [United States], Endo [Ireland], Grnenthal Group [Germany], Arbor Pharmaceuticals [United States], Astellas Pharma Inc. [Japan], Biogen Inc. [United States], Baxter Healthcare Corporation [United States], Sanofi S.A [France], Abbott Laboratories [United States], AstraZeneca [United Kingdom], Johnson & Johnson Services Inc. [United States], GlaxoSmithKline plc [United Kingdom], Depomed Inc. [United States].

Neuropathy pain treatment involves cure of pain associated with somatosensory nervous system. As of 2018 data, 18% of Canadian population, 7% of French and over 4% of United Kingdom population experience pain of neuropathic origin. With growing geriatric population across the world, the number of neuropathic pain causing diseases will increase significantly, thus, giving pain treatment services offering companies an opportunity to explore in untapped market.

Next step one should take to boost sales? Track latest strategic steps and current scenario analysis of the market @ https://www.advancemarketanalytics.com/sample-report/32655-global-neuropathy-pain-treatment-market

Market Segmentation

by Type (Peripheral Neuropathy, Entrapment Neuropathy, Post Traumatic Neuropathy, Trigeminal Neuralgia, Post Herpetic Neuralgia (PHN), Phantom Limb Pain, Others), Indication Type (Diabetic Neuropathy, Trigeminal Neuralgia, Post-herpetic Neuralgia, Chemotherapy-induced Peripheral Neuropathy, Others.), Treatment (Medication, Multimodal Therapy), Distribution Channels (Pharmacies, Retail Pharmacies, Online Pharmacies), End-user (Hospitals, Clinics, Research Organizations), Diagnosis (Imaging, Blood Tests)

Make an enquiry before buying this Report @ https://www.advancemarketanalytics.com/enquiry-before-buy/32655-global-neuropathy-pain-treatment-market

Whats Trending in Market:

Increasing Demand of Generic Drugs

Emergence of Innovative Pain Treatment Methods Such as Use of Electrical Stimulation Devices, Stem Cell Procedures and Others

Growth Drivers: Rising Geriatrics Population Across the World

Growing Number of Cancer and Diabetes Cases

Restraints: High Cost of Neuropathy Pain Treatment

Lack of Health Infrastructure and Budgets in Emerging Countries

View Detailed Table of Content @ https://www.advancemarketanalytics.com/reports/32655-global-neuropathy-pain-treatment-market

Country level Break-up includes:

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Spain, Italy, Netherlands, Switzerland, Nordic, Others)

Asia-Pacific (Japan, China, Australia, India, Taiwan, South Korea, Middle East & Africa, Others)

Try a limited scope research document specific to Country or Regional matching your objective.

GET FULL COPY OF United States Neuropathy Pain Treatment market study @ USD 2000

And, Europe Neuropathy Pain Treatment market study @ USD 2500

Strategic Points Covered in Table of Content of Global Neuropathy Pain Treatment Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Neuropathy Pain Treatment market

Chapter 2: Exclusive Summary the basic information of the Neuropathy Pain Treatment Market.

Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges of the Neuropathy Pain Treatment

Chapter 4: Presenting the Neuropathy Pain Treatment Market Factor Analysis Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.

Chapter 5: Displaying the by Type, End User and Region 2013-2018

Chapter 6: Evaluating the leading manufacturers of the Neuropathy Pain Treatment market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile

Chapter 7: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions.

Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Buy this report @ https://www.advancemarketanalytics.com/buy-now?format=1&report=32655

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Contact Us:

CRAIG FRANCIS (PR & Marketing Manager)

[emailprotected]

Ph: +1 (206) 317 1218

Go here to see the original:

Neuropathy Pain Treatment Market Set For Rapid Growth and Trend | Statistics Analysis and Opportunities 2024 - News Description

The Global Neuropathy Pain Treatment Market is the increasing incidence of neuropathic pain caused by damage or

disease affecting the somatosensory nervous system. Growing awareness among patients and increase in the demand for generic drugs boost the market growth. However, severe side effects of opioids and steroids and rising costs of branded drugs might hamper the market growth

Buy one-Get one: https://www.orianresearch.com/checkout/956157

[Buy this report and get another report of the same price for free. offer for limited period only].

Based on type, the market is divided into:

Based on application, the market is divided into:

Moreover, the market is classified based on regions and countries as follows:

For More Info, Get Sample Report Here @ https://www.orianresearch.com/request-sample/956157

Key Market Players:

Key Benefits of the Report:

Target Audience:

GET Flat 40% Discount https://www.orianresearch.com/discount/956157

[Avail flat 40% discount on this report. offer for limited period only]

Table of Contents

Customization Service of the Report:

Orian Research provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

About Us

Orian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Contact Us:

Ruwin Mendez

Vice President Global Sales & Partner Relations

Orian Research Consultants

US: +1 (415) 830-3727 | UK: +44 020 8144-71-27

Email: [emailprotected]

Website: http://www.orianresearch.com

See the original post:

Global Neuropathy Pain Treatment Profiling Industry 2019 Market Share, Regional Analysis, Growth Insights, Leading Companies, End Users and Forecast...

Rising Prevalence of Cancer Worldwide to Promote Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Growth

A painful dysfunction of the somatosensory nervous system in the body is called chemotherapy-induced peripheral neuropathy or CIPN. It is estimated that chemotherapy-induced peripheral neuropathy affects an estimate of 68.0% patients who undergo within their first month of diagnosis, among which 30% patients are affected on a chronic basis. The rising prevalence of chronic diseases is promoting the growth of Chemotherapy Induced Peripheral Neuropathy Treatment market. According to Fortune Business Insights, the market for Chemotherapy Induced Peripheral Neuropathy Treatment is anticipated to rise exponentially with increasing prevalence of diabetes worldwide.

Browse Complete Report [emailprotected] https://www.fortunebusinessinsights.com/industry-reports/chemotherapy-induced-peripheral-neuropathy-treatment-market-101218

Rising Prevalence of Cancer to Help Generate High Chemotherapy Induced Peripheral Neuropathy Treatment Market Revenues

The increasing prevalence of chronic diseases such as diabetes and cancer are the major factors promoting the Chemotherapy Induced Peripheral Neuropathy Treatment market. The surge in adoption of chemotherapy is significantly helping to increase the prevalence of peripheral neuropathy. Additionally, lack of proper guidelines about chemotherapy heightens the chance of additional incidence of peripheral neuropathy. This is expected to bode well for generating greater percentages of the global Chemotherapy Induced Peripheral Neuropathy Treatment market share.

However, the market may face certain challenges in terms of the lack of awareness about symptoms of chemotherapy-induced peripheral diagnosis, especially in developing nations. Such challenges may hamper the global Chemotherapy Induced Peripheral Neuropathy Treatment market growth in the forecast period.

Get PDF Brochure of this [emailprotected] https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/chemotherapy-induced-peripheral-neuropathy-treatment-market-101218

Some of the companies operating in the global Chemotherapy Induced Peripheral Neuropathy Treatment market include:

Improving Healthcare Infrastructure and Medical Facilities of Developing Nations to Help Asia Pacific Market Grow Significantly

According to the Center for Diseases Control and Prevention (CDC), ABOUT 1,633,390 new cancer cases were reported in the U.S. in 2015, among which, an estimated 595,919 people died of cancer. As per the geographical categorization, North America is currently holding a significant share in the global Chemotherapy Induced Peripheral Neuropathy Treatment market and is anticipated to continue doing the same in the forecast period as well. This is attributable to the rising prevalence of cancer which is further propelling the demand for chemotherapy treatment by patients and their family members.

On the other side, the global Chemotherapy Induced Peripheral Neuropathy Treatment market in Asia Pacific and Europe will also witness remarkable growth rate during the forecast period owing to improving healthcare infrastructure and medical facilities, especially in the developing nations.

Strategic Partnerships to Help Market Players Gain Strong Foothold in Market

As per the report, the global Chemotherapy Induced Peripheral Neuropathy Treatment market highlights some of the major market shareholders significantly driving the market. These companies are mentioned below

Manufactures continue to focus on new product launches and merger and acquisition strategies to increase their customer base and broaden product portfolio. These manufacturers produce new therapeutic methods to maintain a strong foothold in the market. Some of the recent development made by companies are mentioned below

More Trending Topics From Fortune Business [emailprotected]

U.S. Biosimilars Market 2019 Global Technology, Consumption, Segmentation, Growth, Development, Trends and forecasts to 2026

Mass Spectrometer Market Size Overview by Share, Growth Factor, Industry Trends, and Analysis to 2026

About Us

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights, we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Press Release Distributed by The Express Wire

To view the original version on The Express Wire visit Chemotherapy Induced Peripheral Neuropathy Treatment Market to Generate Higher Revenues by Entering into Strategic Collaborations says Fortune Business Insights

The rest is here:

Chemotherapy Induced Peripheral Neuropathy Treatment Market to Generate Higher Revenues by Entering into Strategic Collaborations says Fortune...

Diabetic Peripheral NeuropathyMarket

Diabetic PeripheralNeuropathy-Epidemiology Forecasting Intelligence report provides acomprehensive analysis of the Diabetic Peripheral Neuropathy epidemiology,providing the historical, current, and forecasted data for the United States,European Union 5 (EU5- Germany, Spain, Italy, France and United Kingdom) andJapan during the period from 2018-2028.

Our epidemiology services include:

Incidence andprevalence Diagnosis rate, treatment rate and mortality patterns Epidemiology-based forecasting and disease trends Size of different patient segments in a disease area Population based: disease occurrence, co-morbidities and treatment patterns Geographic Regional Ethnic differences

Along with the epidemiological data, the reportalso includes:

Disease overview,causes, symptoms, classification, risk factor, pathophysiology, diagnosis andtreatment Patient treatment journey Treatment algorithm and guidelines Assesses the disease risk and burden Highlights the unmet needs Market driver and barrier Growth opportunities and market trend analysis

Methodology

This report isbuilt using data and information sourced from proprietary databases, primaryand secondary research and in-house Epidemiology Forecast model analysis by ateam of industry experts. To generate accurate patient population estimates, utilizes a combination ofseveral world class sources that deliver the most up to date information frompatient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have beenidentified in the report.

Note:

Systematic review ofthe epidemiological literature is also provided for full transparency intoresearch and methods. This report can be delivered to the clients within 4-5business days.

Request customize:-

If you wish to find more details ofthe report or want a CustomizationPlease contacts us. You can get adetailed of the entire research here.

Ozone Market Reports is committed towards delivering intensiveresearch based analysis reports, enabling clients to easily make fact-baseddecisions. We also have with us the facility of our innovatively designed anddeveloped data processing and analysis division.

Ozone Market Reports is a research-based consulting firmspecializing in getting research inputs and using them appropriately in themarketing planning process. In saying this, we are trying to convey that wealways attempt to interpret the research data from the viewpoint ofrecommending action priorities both short-term and long-term. To this end, wehave put together a team that understands not only research techniques, butalso branding concepts in depth.We believe our people are our clientsbiggest assetshence we do our best to recruit multi-skilled individuals,and then give them an environment where they can think and ideate freely.

We offer various services for our clients to help them choosewhats most relevant and best for them required for their business.

Contact Us:

Name: Steven Samuel

Email info@ozonemarketreports.com

Phone +91 9370882135

Website: https://www.ozonemarketreports.com/

Post Views: 70

Read the original post:

Diabetic Peripheral Neuropathy Market - Growth, Future Prospects, and Competitive Analysis 2028 - Market Tribunal

For patients with diabetes, cardiovascular disease should be a top priority.

Nathan D. Wong, PhD, director of the Heart Disease Prevention Program at the University of California, Irvine, is a co-author of the Heart Disease and Diabetes chapter in the NIDDK publication Diabetes in America, 3rd Edition. Here he talks about the importance of broadening the clinical focus of diabetes care from hemoglobin A1C to also include other risk factors for cardiovascular disease common in patients with diabetes.

Q: Why is it so important to talk about heart disease with patients who have diabetes?

A:More than two-thirds of patients with diabetes will die of cardiovascular-related illnesses such as coronary heart disease, stroke, heart failure, and peripheral arterial disease. For women with diabetes, the risks for different forms of cardiovascular disease are three to seven times greater compared with women who do not have diabetes. For men with diabetes, the risk is two to three times greater.

We are doing a poor job of managing heart disease in people with diabetes in this country and throughout the world, despite many advances in therapies over the past 30 years. We still have a very small percentage of people with diabetesfewer than one in fivewho meet appropriate targets for hemoglobin A1C, blood pressure, and LDL cholesterol; even fewer additionally meet the recommendations for physical activity, a healthy diet, nonsmoking status, and body mass index.

Many of these factors have an impact on risk for certain microvascular complications associated with diabetes such asretinopathy, nephropathy, and neuropathy. But these factors also affect risk for macrovascular complications such as heart disease and stroke.

Q: How does cardiovascular risk differ for type 1 and type 2 diabetes?

A:When people are diagnosed with type 2 diabetes, they often already have hypertension and dyslipidemia. For people with type 1 diabetes, the diagnosis generally comes when theyre much younger, so they arent yet at significant cardiovascular risk. Theres a true opportunity to help prevent them from developing cardiovascular risks in the first place, rather than trying to catch up with these factors after theyve developed and are more difficult to control.

Q: What are the benefits of keeping all the cardiovascular risk factors at target levels?

A: The Steno 2 clinical trial found a 53% risk reduction in cardiovascular outcomes for people with type 2 diabetes who were intensively treated for risk factors, compared with participants in the control group. In a follow-up paper, the researchers reported on mortality rates after 13 years. They found it was significantly lower for the intensively treated group. Just 30% had died, compared with 50% of the conventionally treated group.

In an observational study, we pooled data on people with diabetes from three different clinical trials to show an approximately 60% lower risk for developing coronary heart disease or cardiovascular disease in people with diabetes who were at target levels for LDL cholesterol, blood pressure, and hemoglobin A1C. This suggests we can possibly reduce the risk of future heart attacks or strokes by more than half, if we ensure that these factors are controlled.

Q: What does this mean for diabetes care?

A:We still have a lot of work to do to get the word out that diabetes is really a cardiovascular condition. Most people with diabetes are not dying from retinopathy or neuropathy; they are dying from cardiovascular disease. This is not to trivialize the microvascular complications. Obviously, neuropathy or retinopathy can significantly affect quality of life. But in terms of what a person with diabetes eventually will die of, its cardiovascular disease. Patients and their health care providers really have to better understand that controlling diabetes is much more than controlling blood sugar.

Certainly, managing glucose is critical to prevent microvascular complications, in particular. There is strong epidemiologic data that adverse cardiovascular outcomes are greater in people with higher levels of hemoglobin A1C, but the evidence is less striking for improving cardiovascular outcomes from glucose control alone. And in fact, the ACCORD trialactually showed increased cardiovascular mortality to occur when targets were set too aggressively for hemoglobin A1C.

Q: How can the message on cardiovascular risk factors reach more health care professionals?

A:I think theres tremendous opportunity to advance professional education to help improve cardiovascular outcomes in people with diabetes. And this, of course, can be accomplished with lifestyle changes. But few people with diabetes see a dietician and/or exercise physiologist as frequently as they should to help them with theirdiabetes self-management. These allied health care providers are not traditionally part of the health care team as much as they should be, because reimbursement is not always available for their services. Physicians need to know that these resources exist, and that they can also prescribe lifestyle improvements such as walking or eating more vegetables.

At professional meetings, I've asked for a raise of hands: How many of you physicians have heard of the American Medical Association? Virtually all of them have. Then I ask, How many of you have heard of theAcademy of Nutrition and Dietetics? Very few have, yet this is a very powerful group. Specifically, the Academys Sports, Cardiovascular and Wellness Nutrition dietetic practice group includes close to 10,000 people around the country. The American College of Sports Medicine includes exercise physiologists. But there's a disconnect. We need to help physicians know that these other providers, who are key to patients success in managing their diabetes and cardiovascular risks, exist.

Q: How can cardiologists contribute to better care for patients with diabetes?

A:The American College of Cardiology advocates for cardiologists to learn more about how to manage diabetes. This is largely fueled by the fact that we now have newer medications that are shown to reduce cardiovascular events in people with diabetes. These drugs are not the most powerful A1C-lowering agents, but theyre the only agents shown to have benefits in terms of cardiovascular outcomes. The sodium-glucose cotransporter-2 (SGLT2) inhibitors, in particular, have the dramatic effect of reducing heart failure-related hospital stays by more than 30%. Equally exciting are the glucagon-like peptide-1 (GLP-1) receptor agonists, which seem to have more of an anti-atherosclerotic effect.

Both of these therapies have been incorporated into several guidelines. The American College of Cardiology, the American Association of Clinical Endocrinologists, the American Diabetes Association, and the American Heart Association recommend these therapies specifically for people with pre-existing diabetes and cardiovascular disease.

But its mainly the specialty community that has started to use these therapies. We need to increase efforts to communicate the value and the indications of these therapies among primary care providers, too.

Q: What advice do you have for health care professionals so that they can better help their patients with diabetes manage the cardiovascular risk factors?

A:Providers and patients with diabetes alike need to understand that cardiovascular disease should be their main concern. It takes a concerted approach to manage all the relevant risk factors to significantly improve outcomes. Were talking about a multidisciplinary cardio-diabetes care team that includes lifestyle specialistsdieticians and physical activity expertsas well as other appropriate specialists, including the endocrinologist and the cardiologist, and, in many cases, the primary care provider at the center of the patients care.

Health care professionals also need to motivate patients to take greater charge in their health care.Shared decision-making is very important in starting new therapies and managing lifestyle changes.

What has been your experience addressing cardiovascular risk in your patients with diabetes? Tell us below in the comments.

Follow this link:

Addressing Cardiovascular Risk Factors in People with Diabetes - National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

The Inherited Neuropathy Consortium led by University of Iowa neurologist Michael Shy has received a grant renewal to continue studying inherited neuropathies.

The Carver College of Medicine is pictured on Wednesday, April 4, 2018.

Gaoyuan Pan

The Carver College of Medicine is pictured on Wednesday, April 4, 2018.

Gaoyuan Pan

Gaoyuan Pan

The Carver College of Medicine is pictured on Wednesday, April 4, 2018.

As clinical research of medical technology advances, so will the understanding of genetic neurological diseases. The National Institute of Health has renewed the University of Iowas grant to study inherited neuropathic diseases.

The Inherited Neuropathy Consortium, located in the UI Carver College of Medicine, recently received a five-year $7.2 million grant renewal to continue researching inherited peripheral neuropathies in the hope of finding a cure for related diseases.

Peripheral neuropathies are disorders affecting the nerves that spread from someones back to their hands and feet, which can cause weakness and balance problems, UI neurologist Michael Shy said. Although these disorders have many causes, he said, a common cause is a genetic mutation that can disrupt the nerves.

Shy said the diseases are referred to as Charcot-Marie-Tooth type 1 or type 2, depending on which part of the nerve the disease affects. These diseases are fairly common and affect one in 2,500 people, he added.

Up until 1990, there were no known genetic causes for any of these, although it was known that the diseases could be genetic, Shy said. Now theres mutations in over 100 different genes that can cause these disorders.

The consortium works with other institutions around the world to determine how these diseases change over time, identify other genetic causes of Charcot-Marie-Tooth, and train physicians to study and treat the diseases, Shy said.

With the grant renewal, the consortium will continue its study of how Charcot-Marie-Tooth changes over time through using different outcome measurements they have developed and new instruments allowing them to measure outcomes in infants, Shy said.

RELATED: UI doctors prepare to study obscure leading cause of death in refractory epilepsy

The grant will also allow researchers to continue to identify and study biomarkers in patients blood that are common for Charcot-Marie-Tooth, he said.

Even though clinical trials have been developed to treat the diseases, there is no cure, Shy said. The clinic emphasizes genetic counseling to help people understand their condition and the potential it has to pass on to other generations, he said.

Counselors meet with families to discuss genetic testing options, provide an understanding of what their insurance will cover, and an understanding of the various lab testing they will receive, said Shawna Feely, genetic counselor and clinic coordinator.

Feely is the consortiums project manager and oversees the 20 sites involved. She helps research teams navigate protocols, understand the testing, and create uniformity in the way clinical trials are conducted.

RELATED: University of Iowa receives grant to improve statewide-maternal-health

Any time youre giving a genetic diagnosis, there can be an emotional element to the person or family in terms of family dynamics or feeling guilt that someones passed a genetic disease on, and so genetic counselors part of the counseling part is to help families cope, Feely said.

Genetic counselor Tiffany Grider said in an email to The Daily Iowanthat a common question from patients is whether or not their child will have the same condition, and whether theres a treatment for it.

Researchers like Dr. Shy have spent decades learning the exact biological mechanism for how these diseases happen, Grider said.

With the developing research and the grant, the future of the clinic and genetic testing will be in the hands of the next generation, Shy said.

Its this next generation of scientists who are going to take this to the clinic, so these are going to become treatable diseases, Shy said. And we need that generation to be well-trained to be able to develop [treatments].

Read the original:

UI-led neuropathy consortium receives grant renewal from National Institute of Health - UI The Daily Iowan

In 2018, the market size of Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2018; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.

In this report, 2018 has been considered as the base year and 2018 to 2025 as the forecast period to estimate the market size for Stroke Prevention in Atrial Fibrillation (SPAF) Treatment .

This report studies the global market size of Stroke Prevention in Atrial Fibrillation (SPAF) Treatment , especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).

Request Sample Report @ https://www.researchmoz.us/enquiry.php?type=S&repid=2525974&source=atm

This study presents the Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market production, revenue, market share and growth rate for each key company, and also covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. Stroke Prevention in Atrial Fibrillation (SPAF) Treatment history breakdown data from 2014 to 2018, and forecast to 2025.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2018.

In global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment market, the following companies are covered:

Boehringer IngelheimBayerJohnson & JohnsonBristol-Myers SquibbPfizerDaiichi-SankyoGilead

Segment by RegionsNorth AmericaEuropeChinaJapanSoutheast AsiaIndia

Segment by TypeOral Direct Thrombin InhibitorsOral Direct Factor Xa Inhibitors

Segment by ApplicationHospitalsClinicsAmbulatory Surgical Centers

Make An EnquiryAbout This Report @ https://www.researchmoz.us/enquiry.php?type=E&repid=2525974&source=atm

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of Stroke Prevention in Atrial Fibrillation (SPAF) Treatment , with price, sales, revenue and global market share of Stroke Prevention in Atrial Fibrillation (SPAF) Treatment in 2017 and 2018.

Chapter 3, the Stroke Prevention in Atrial Fibrillation (SPAF) Treatment competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Stroke Prevention in Atrial Fibrillation (SPAF) Treatment breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2018.

Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2018.

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2525974&licType=S&source=atm

Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2018.

Chapter 12, Stroke Prevention in Atrial Fibrillation (SPAF) Treatment market forecast, by regions, type and application, with sales and revenue, from 2018 to 2024.

Chapter 13, 14 and 15, to describe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Read the rest here:

Cardiac Autonomic Neuropathy Treatment Market expected to Witness a Sustainable Growth over 2017 2025 - Health News Office

HOUSTON Deborah Brancato has worked as a flight attendant for 25 years, but after undergoing chemotherapy to treat breast cancer, she developed neuropathy. The pain in her feet was so bad she was not able to stand for long periods of time and couldn't wear the required closed-toed shoes that were part of her uniform.

Brancato needed to find a solution to treat the pain she experienced from neuropathy. She found help at Advanced Nerve and Health Center, where patients of Dr. Bao Thai are seeing amazing results. Dr. Thai has developed a non-invasive, pain free treatment that helps the body repair nerves without surgery or medication.

Dr. Thai is a pioneer in this field, and has studied all over Europe and Asia exploring technologies and processes. He conducted his own research and found that the body wants to heal the nerve, and over time it will heal.

The Advanced Nerve and Health Center has a limited time offer for Great Day Houston viewers. For $39, the first 17 callers will get an in-office consultation, a copy of Dr. Thai's "Healthy Diet to Heal Nerve Pain" book, and a diagnostic nerve test to see if they can help. This is a $399 value.

Call Advanced Nerve and Health Center now at 832-626-1260.

Advanced Nerve and Health Center is located at 8558 Katy Freeway, Suite 116, Houston, TX 77024.

For more information, log on to NerveAndHealth.com.

This content is sponsored by: Advanced Nerve and Health Center.

Here is the original post:

Advanced Nerve & Health Center helps breast cancer survivor reverse her neuropathy - KHOU.com

TheDiabetic Neuropathy Market is a professional and in depth market reportthat focuses on primary and secondary drivers, possible sales volume, market share, leading segments, market size and geographical analysis of the market. It shows that the increase in market value is generally attributed to the increasing growth of the applicable industries and the subsequent increase in demand for applications. The Diabetic Neuropathy market analysis examines the different segments that are relied on to witness the fastest growth in the approximate forecast frame. The competitive landscape section of the Diabetic Neuropathy report provides a clear insight into the market share analysis of major industry players.

Diabetic Neuropathy Market: Scope of the Report :

This report provides an all-inclusive environment of the analysis for the Diabetic Neuropathy Market. The market estimates provided in the report are the result of in-depth secondary research, in-house expert reviews, and primary interviews. These market estimates have been considered by studying the impact of various social, political and economic factors along with the current market dynamics affecting the Diabetic Neuropathy Market development. In addition to the description of the market, which includes market dynamics, the chapter includes Porters Five Forces analysis which explains the five forces; namely buyers bargaining power, suppliers bargaining power, the threat of new entrants, threat of substitutes, and degree of competition in the Diabetic Neuropathy Market. The report also focuses on the competitive landscape of the Diabetic Neuropathy Market.

For Better Understanding Go With this Free Sample Report Enabled with Respective Tables and Figures:https://marketresearch.biz/report/diabetic-neuropathy-market/request-sample

Diabetic Neuropathy Market: Competitive Landscape

The market analysis entails a section solely dedicated to major players in the Diabetic Neuropathy Market wherein our analysts provide an insight into the financial statements of all the major players, along with its key developments, product benchmarking and SWOT analysis. The Company Profile section also comprises a business overview and financial information. The companies that are provided in this section can be customized according to the clients requirements.

There are some key players Pfizer Inc, Eli Lilly and Company, Actavis Pharma Inc, Cephalon Inc, Meda Pharma GmbH, GlaxoSmithKline plc, NeuroMetrix Inc, Johnson & Johnson Inc, Boehringer Ingelheim GmbH, Astellas Pharma Inc.

Diabetic Neuropathy Market Segments:

Segmentation on the basis of disorder type:

Peripheral neuropathyAutonomic neuropathyProximal neuropathyFocal neuropathySegmentation on the basis of treatment:

RadiotherapyPhysiotherapy

Key Questions Answered by This Report:

How did the market evolve and what is the market status in 2019?

What are the drivers and restraints of the Market?

What are the opportunities for growth within the market and where do the major threats lie?

How will each submarket segment grow in the near future and how much market value will each segment generate for 2019 2028?

How the political, economic, social, and technology factors influence the submarkets and regional market?

How will individual leading Worldwide markets perform over the forecast period, and what are their drivers and restraints?

What have been the major developments of the leading Worldwide markets over recent years, leading to their current market status?

How will the market shares of the regional and leading Worldwide markets evolve by 2019 2028, and which geographical region will lead in 2019 2028?

Who are the key players within the market, and what are their strategies over the forecast period?

Share Your Questions Here For More Details On this Report or Customizations As Per Your Need:https://marketresearch.biz/report/diabetic-neuropathy-market/#request-for-customization

In more detail, the chapters of this report contain the following topics:

Chapter 1 It consists of research objective and assumption, research objectives of the report

Chapter 2 Introduces the market; discusses the different segmentations of the market; summaries the report

Chapter 3 Includes market drivers, restraint, opportunity, and trends contributing to the growth of the market. The dynamic section of the report also includes DR Impact Analysis, Opportunity Orbit, PEST Analysis, and Porters Five Analysis.

Chapter 4 Studies the global market, providing market shares and sales figures. The chapter also analyses market forecasts, factors enabling growth, and the future of the market, covering the period 2018-2029. Furthermore, it provides in-depth detailed analyses and forecasts of the submarkets.

Chapter 5 provides an in-depth and thorough analysis of the regional and Worldwide markets. The chapter continues by supplying market forecasts, details on growing regions, factors enabling the growth, drivers, and restraints on a Worldwide basis, developments over 2015 and their influence over the forecast period, and future market predictions, covering the period 2018-2029.

Chapter 6 Identifies, discusses and analyzes the leading players in the market, as well as innovative, growing companies that will impact the future of the industry.

Chapter 7 Explains the research methodology the company follows to create, enriched insights to clients from millions of data points.

Inquire/Speak To Expert for Further Detailed Information About Diabetic Neuropathy Report:https://marketresearch.biz/report/diabetic-neuropathy-market/#inquiry

Excerpt from:

PDF Report : Diabetic Neuropathy Market 2019 || Comprehensive Analysis of the market with Competitive Landscape and Forecasts To 2028 - Tech News...

October is Breast Cancer Awareness Month. In some ways, the month is a celebration of the many advances made toward diagnosing and treating breast cancer at its very earliest stages. With these earlier identifications come the expectations for more favorable treatment and survival outcomes.

That said, when a cancer diagnosis is delivered, the individual receiving it often hears nothing but I have cancer. Words like these can be overwhelming. It begins a search to gather and develop the most competent team to lead you through this journey.

There are many options when considering breast cancer surgery. Those are for you and your surgical team to examine. Perhaps you have chosen to pursue a lumpectomy or a mastectomy. These procedures might include lymph nodes being removed in the axilla (the armpit), to discover if a cancer has spread elsewhere.

But what happens after a tumor has been removed? Surgical intervention can deliver a whole new set of concerns including:

n Tissue adhesions that can lead to postural changes

n Impaired shoulder function

n Pain and subsequent movement compensations

n Seromas

n Hematomas

n Serratus anterior weakness

n Axillary web syndrome/cording (scarring or connective tissue under the arm that can limit range of motion)

Lymphedema is also a common side effect following breast cancer surgery. It occurs after the lymph nodes have been removed or damaged, impairing normal lymphatic flow in the arm, which causes the arm to swell.

Your plan of care might also include radiation or chemotherapy. If radiation is part of your treatment, there can be temporary tissue adhesions; reduced shoulder and trunk range of motion; inflammatory edema (swelling caused by excess fluid); and pain. You may also experience permanent changes called radiation fibrosis, which is scar tissue that can occur in the breast and chest wall.

If your oncology team decides chemotherapy is warranted, challenges from the treatment can include pain; fatigue; poor tolerance to activity; neuropathy; weakness; and an increased risk of cardiovascular disease.

Regardless of your breast cancer treatment approach, every survivors plan for recovery should include treatment for whatever physical changes you may experience. It is imperative to see a physical therapist and certified lymphedema therapist early on to ensure the best results.

A therapist trained in breast cancer rehabilitation can work with you to:

n Address shoulder, complex movement, and soft tissue disorders

n Improve your comfort and function during and following breast reconstruction

n Address effects of radiation

n Reduce fatigue and weakness

n Develop an individualized home exercise program

St. Peters Health Partners Patient Therapies has a variety of outpatient physical therapists at locations throughout the Capital District, accepting all insurances and providing quality one-on-one treatment. Our staff works closely with your oncology and/or primary care team to help decrease pain, improve flexibility, and reduce effects of scar tissue adhesions/radiation fibrosis.

If you are seeking treatment for lymphedema, our therapists have received specialized training in manual lymph drainage and compression bandaging. We have the longest operating lymphedema management program in the Capital District.

For information, call 518-268-5749 or visit us at http://www.sphp.com/patient-therapies.

See more here:

Surviving breast cancer what comes next? - Hudson Valley 360

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the global diabetic neuropathy drugs market since 2016 and the market is poised to grow by USD 866.72 million during 2019-2023, progressing at a CAGR of about 6% during the forecast period. Request Free Sample Pages

Read the 135-page research report with TOC on "Diabetic Neuropathy Drugs Market Analysis Report by Mechanism of action (calcium channel alpha-2-delta ligand, SNRIs and TCAs, and others), by Geography (Asia, Europe, North America, and ROW), and Segment Forecasts, 2019 - 2023."

The market is driven by the approval of new drugs and the presence of a strong drug pipeline. In addition, the development of novel biologics to treat diabetic neuropathy is anticipated to further boost the growth of the diabetic neuropathy drugs market.

Market vendors are increasingly focusing on the development of disease-modifying drugs to treat diabetic neuropathy due to its growing prevalence. The market is witnessing an increase in the number of approvals of drugs such as LYRICA CR extended-release tablets. These drugs are used to manage neuropathic pain associated with diabetic peripheral neuropathy. In addition, there are several drugs that are in the last-stages of the pipeline. VM202 is an investigational therapy that is currently in Phase III clinical trials. Thus, approval of such new drugs and the presence of a strong drug pipeline is expected to drive market growth during the forecast period.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for FREE.

View market snapshot before purchasing

Major Five Diabetic Neuropathy Drugs Market Companies:

Pfizer Inc.

Pfizer Inc. is headquartered in the US and owns and operates businesses under various segments such as innovative health and essential health. The company offers LYRICA and NEURONTIN. LYRICA is used to treat diabetic nerve pain.

Novartis AG

Novartis AG is headquartered in Switzerland and manufactures products through several business segments such as innovative medicines, sandoz, and alcon. The company offers Tegretol, which is an anticonvulsant medication used in the treatment of neuropathic pain.

Johnson & Johnson Services, Inc.

Johnson & Johnson Services, Inc. is headquartered in the US and has business operations under various segments, namely pharmaceutical, medical devices, and consumer. The company offers NUCYNTA, which is an opioid analgesic used to treat diabetic neuropathy pain.

Eli Lilly and Company

Eli Lilly and Company is headquartered in the US and offers products through business segments such as human pharmaceutical products and animal health products. The company offers CYMBALTA, which is used to treat neuropathic pain.

DAIICHI SANKYO COMPANY, LIMITED

DAIICHI SANKYO COMPANY, LIMITED is headquartered in Japan and offers products through business segments such as innovative pharmaceuticals business and generic business. The company offers Tarlige, which is used to treat peripheral neuropathic pain.

Register for a free trial today and gain instant access to 10,000+ market research reports. Technavio's SUBSCRIPTION platform

Diabetic Neuropathy Drugs Mechanism of Action Outlook (Revenue, USD Million, 2019 - 2023)

Diabetic Neuropathy Drugs Regional Outlook (Revenue, USD Million, 2019 - 2023)

Technavios sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

Related Reports on Health Care are:

Pericarditis Drugs Market Global Pericarditis Drugs Market by product (NSAIDs, colchicine, and others) and geography (Asia, Europe, North America, and ROW).

Blepharitis Drugs Market Global Blepharitis Drugs Market by product (steroids and antibiotics) and geography (Asia, Europe, North America, and ROW).

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavios report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Continued here:

Diabetic Neuropathy Drugs Market 2019-2023 | Evolving Opportunities with Pfizer Inc. and Novartis AG | Technavio - Business Wire

Anxiety is a common response to an increasingly demanding society and work culture. We are surrounded by physical and mental stressors that may impact the body in ways that mirror peripheral neuropathy symptoms.

For caregivers and patients suffering from familial amyloid polyneuropathy, it is important to be aware of how stress affects peripheral neuropathy symptoms and to distinguish the differences in bodily reactions to these stressors.

The symptoms of stress may be similar to those of peripheral neuropathy. That includes the constricting of blood vessels due to hyperventilation and seemingly hyperactive nerve activity.

Patients who are prone to anxiety attacks must be aware of how their hands, feet, and arms are feeling. The constriction of blood cells caused by hyperventilation may increase tingling and burning sensations in the peripheral nerves. Patients and caregivers should be aware of how reduced blood flow due to hyperventilation may impact existing peripheral neuropathy symptoms.

Anxiety may also cause increased nerve reactions in the body. The increase in nerve firings may cause cramps and symptoms similar to nerve damage. As these symptoms may feel similar to those caused by peripheral neuropathy, caregivers and patients must be diligent in having both topical treatments and stress-relieving exercises readily available.

Breathing exercises may help patients relax during times of increased stress. During hyperventilation, patients should breathe in deeply, holding each breath for a few seconds and then slowly breathing out for seven to 10 seconds. This exercise helps patients relax their bodies and may help to reduce the effects of hyperventilation caused by anxiety.

Spending time with loved ones helps patients distract themselves from stressors that may cause anxiety. Being around people whose company a patient enjoys may help increase feelings of happiness. Activities may include spending time with children, traveling with family, or spending holidays together.

My mother-in-laws preferred method of battling anxiety and depression is by spending time with her loved ones. She is rooted in her family. The time spent with them provides her with a sense of purpose and a distraction from her bodily pains. They are her support center when she needs it.

Massage therapy may help patients relax their bodies and reduce the impact of peripheral neuropathy symptoms. Relaxing the body is an effective way to mitigate the effects of anxiety. When pursuing massage therapy, caregivers need to understand their patients thresholds for touch. Applied pressure may cause increased pain and essentially negate the desired outcome for massage therapy.

Massage therapy may include self-administered massages, professional massages, and foot massages. The ultimate goal for patients pursuing massage therapy for anxiety is to relax the body while providing a mental distraction that reduces the symptoms.

What are some ways that you reduce stress or anxiety? Please share in the comments below.

***

Note: FAP News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of FAP News Today or its parent company, BioNews Services, and are intended to spark discussion about issues pertaining to familial amyloid polyneuropathy.

Sorry! The Author has not filled his profile.

See the original post:

How Caregivers and Patients Can Manage Bodily Responses to Stress - FAP News Today